121 related articles for article (PubMed ID: 22045360)
1. Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays.
Ramirez AB; Lampe PD
Cancer Biomark; 2010-2011; 8(4-5):293-307. PubMed ID: 22045360
[TBL] [Abstract][Full Text] [Related]
2. Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens.
Draghici S; Chatterjee M; Tainsky MA
Expert Rev Mol Diagn; 2005 Sep; 5(5):735-43. PubMed ID: 16149876
[TBL] [Abstract][Full Text] [Related]
3. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
4. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays.
Gunawardana CG; Memari N; Diamandis EP
Clin Biochem; 2009 Mar; 42(4-5):426-9. PubMed ID: 19094976
[TBL] [Abstract][Full Text] [Related]
5. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
[TBL] [Abstract][Full Text] [Related]
6. Antibody microarrays as tools for biomarker discovery.
Sanchez-Carbayo M
Methods Mol Biol; 2011; 785():159-82. PubMed ID: 21901599
[TBL] [Abstract][Full Text] [Related]
7. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers.
Miller JC; Zhou H; Kwekel J; Cavallo R; Burke J; Butler EB; Teh BS; Haab BB
Proteomics; 2003 Jan; 3(1):56-63. PubMed ID: 12548634
[TBL] [Abstract][Full Text] [Related]
8. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
9. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
13. Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput.
Chatterjee M; Wojciechowski J; Tainsky MA
Methods Mol Biol; 2009; 520():21-38. PubMed ID: 19381945
[TBL] [Abstract][Full Text] [Related]
14. A biotin label-based antibody array for high-content profiling of protein expression.
Huang R; Jiang W; Yang J; Mao YQ; Zhang Y; Yang W; Yang D; Burkholder B; Huang RF; Huang RP
Cancer Genomics Proteomics; 2010; 7(3):129-41. PubMed ID: 20551245
[TBL] [Abstract][Full Text] [Related]
15. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
17. SELDI-TOF MS profiling of plasma proteins in ovarian cancer.
Wu SP; Lin YW; Lai HC; Chu TY; Kuo YL; Liu HS
Taiwan J Obstet Gynecol; 2006 Mar; 45(1):26-32. PubMed ID: 17272204
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics and biomarker discovery.
Johann DJ; McGuigan MD; Patel AR; Tomov S; Ross S; Conrads TP; Veenstra TD; Fishman DA; Whiteley GR; Petricoin EF; Liotta LA
Ann N Y Acad Sci; 2004 Jun; 1022():295-305. PubMed ID: 15251975
[TBL] [Abstract][Full Text] [Related]
19. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
Carlsson A; Wingren C; Ingvarsson J; Ellmark P; Baldertorp B; Fernö M; Olsson H; Borrebaeck CA
Eur J Cancer; 2008 Feb; 44(3):472-80. PubMed ID: 18171612
[TBL] [Abstract][Full Text] [Related]
20. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
